| Released | Contributor | Author | Title | Pages | Price |
|---|
| May 23, 2013 | Alpha Street Research | Hunter Orr | COV - Covidien Plc - Upgraded to a Buy - Company Analysis and ASR Ranking Report | 9 | $24 | | May 22, 2013 | Plunkett Research, Ltd. | Jack W Plunkett | Covalon Technologies Ltd. (COV) Profile and Financials, plus Health Care Industry Trends Analysis, Operating Ratios and Financial Averages | 52 | $99 | | May 22, 2013 | New Constructs, LLC | N/A | COV: Due Diligence Review: Forensic Earnings and Valuation | 13 | $25 | | May 22, 2013 | Plunkett Research, Ltd. | Jack W Plunkett | Covidien plc (COV) Profile and Financials, plus Biotechnology Industry Trends Analysis, Operating Ratios and Financial Averages | 48 | $99 | | May 22, 2013 | Plunkett Research, Ltd. | Jack W Plunkett | Covidien plc (COV) Profile and Financials, plus Health Care Industry Trends Analysis, Operating Ratios and Financial Averages | 51 | $99 | | May 22, 2013 | Thomson Reuters Stock Report | StockReports + Research Department | Thomson Reuters Stock Report - COVIDIEN PLC (COV-N) | 12 | $25 | | May 22, 2013 | ValuEngine, Inc. | N/A | ValuEngine Detailed Valuation Report for COV | 11 | $126.50 | | May 22, 2013 | ValuEngine, Inc. | N/A | ValuEngine - Toronto Quantitative Stock Report for COV | 11 | $126.50 | | May 22, 2013 | ValuEngine, Inc. | N/A | ValuEngine Industry Report for Medical Products | 17 | $195.50 | | May 19, 2013 | Market Edge | N/A | Market Edge Equity Research Report | 4 | $10 |
|
View All Reports for COV ... |
|
|
0.08%